



WHO EML Secretariat June 21, 2021

John Wiernikowski, PharmD, FISOPP, FCAPhO
McMaster Children's Hospital, McMaster University
On Behalf of the International Society of Oncology Pharmacy Practitioners (ISOPP)



With Respect to the Following Drugs for Proposed Addition to the WHO EML

- Anti-PD1 Inhibitors, Anakinra, BRAF/MEK Inhibitors, CDK 4,6 Inhibitors, Osimertinib, Pertuzumab, Ibrutinib, Fulvestrant, Daratumumab, Tislelizumab, Zanubrutinib
- Rasburicase



ISOPP Recommendations to EML Secretariat

- Addition of Rasburicase to the EML
 - Despite cost, real world use of this agent in management of emergent/established TLS in high risk populations can be very cost effective.
- For Remaining Drugs
 - Cost implications for LMICs are daunting
 - Suggest WHO & Partners work towards getting high quality biosimilar/generic medicines developed for LMICs
 - Invest in health system infrastructure to support the cost-effective use of these agents
 - Biomarker/Molecular Testing
 - Invest in Human Resources to support cost effective/safe use of these new agents
 - <https://journals.sagepub.com/doi/full/10.1177/10781552211017199>
- Develop Standardized Treatment Regimens for LMICs